Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04837352
Other study ID # RC-P00105
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 18, 2022
Est. completion date October 18, 2025

Study information

Verified date March 2024
Source Lille Catholic University
Contact Marie-Paule Lebitasy, MD, PhD
Phone 03.20.22.52.69
Email Lebitasy.Marie-Paule@ghicl.net
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this study is to assess the role of sociocognitive and interpersonal factors in the therapeutic adherence of multiple sclerosis patients. This study will provide a better understanding of the socio-psychological issues associated with different types of non-adherence to treatment, and identify the risk factors and vulnerability of each patient.


Description:

Multiple sclerosis is a chronic and progressive disease that affects young adults (between 20 and 40 years old), impacting significantly the patients quality of life. The adherence to therapy affects the long-term functional clinical course (lower risk of relapses, reduction in disability progression and quality of life). The non-adherence rate to therapy in multiple sclerosis is estimated at 40%. The main identified causes of non-adherence are: forgetting to take treatment and adverse effects of drugs. Sociocognitive models as the Theory of Planned Behaviour (TPB) have been developed to help to understand and predict health-related behaviours. This model postulates that the intention to adopt a behaviour is one of the major determinants in the context of health. This intention comes from three independent elements : - Personal positive or negative attitudes towards the behaviour, - Social expectations or entourage perception (subjective norms), - Difficulty in accomplishing this behaviour (perceived control) Multiple sclerosis adherence to therapy studies have mainly focused on somatic variables (physical disability, illness duration, type of treatment) and some clinical variables (cognitive impairment, fatigue, depression). The few studies that have examined the multiple sclerosis therapeutic adherence determinants have mainly taken a one-dimensional perspective, such as perceived control. In the FELSA-SEP study, the role of sociocognitive factors (norms and beliefs, perceived threat to disease and health behaviours) and interpersonal factors (social support, patient-doctor relationship) will be explored.


Recruitment information / eligibility

Status Recruiting
Enrollment 153
Est. completion date October 18, 2025
Est. primary completion date January 18, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Multiple sclerosis defined according to McDonald criteria; - Already undergone or beginning substantive treatment (self-managed, excluding treatment administered in hospital) - Aged = 18 years; - Given the informed consent form. Exclusion Criteria: - Severe cognitive impairment (score below the 5th percentile); - Any associated neurological pathology or serious or chronic somatic disease (cancer); - Being under a legal protection measure.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Study of the role of sociocognitive factors
Questionnaires

Locations

Country Name City State
France CHRU DE Bordeaux Bordeaux
France Hôpital Saint-Vincent de Paul Lille
France Hôpital Saint-Philibert Lomme
France CHRU de Strasbourg Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
Lille Catholic University

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Therapeutic adherence evaluated by a Likert scale This 19-item self-questionnaire provides 5 sub-scores corresponding to each of the sub-dimensions (Attitudes, Subjective norms, Perception of control, Behavioural intention and Behaviour) and an overall score (sum of the 5 sub-scores). 6 months
Secondary Perceived threat measured with a self-assessment form The perceived threat will be measured with a self-assessment form using a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree). This 11-item self-questionnaire provides 2 sub-scores and an overall score (sum of the 2 sub-scores). 3 weeks
Secondary Perceived interpersonal relationships quality measure by the perceived social support questionnaire (QSSP) The QSSP is a 6 items questionnaire which assess availability and satisfaction with respect to perceived social support.
4-Point ordinal Alliance Scale (11-items 4-PAS). This self-questionnaire concerns the patient's perception about the therapeutic alliance.
6 months
Secondary Perceived interpersonal relationships quality measure by the 4-Point ordinal Alliance Scale (11-items 4-PAS) The 4-Point ordinal Alliance Scale (11-items 4-PAS). This self-questionnaire concerns the patient's feelings about the therapeutic alliance and includes eleven items, placing the patient on 5-point scale on : the patient's feeling about the doctor's ability to help him/her; his/her understanding of the symptoms of the illness; the psychological improvement felt; the adaptation to the doctor-patient relationship; the doctor's availability and competence; the clarity of the information given by the doctor and the understanding he/she shows; the doctor's desire of clinical improvement; the quality of the relationship and the understanding of psychological difficulties 6 months
Secondary Illness duration in days In order to evaluate the vulnerability and protective factors related to somatic disease illness duration will be evaluated. 3 weeks
Secondary Handicap will be evaluated by the Expanded Disability Status Scale (EDSS) In order to evaluate the vulnerability and protective factors related to somatic the handicap will be evaluated by the EDSS. The EDSS quantifies disability in eight Functional Systems (FS) by assigning a Functional System Score in each of these functional systems.
The clinical meaning of each possible result goes from 0.0: Normal Neurological Exam to 10.0: Death
3 weeks
Secondary Relapses number In order to evaluate the vulnerability and protective factors related to somatic disease number of relapses will be evaluated 3 weeks
Secondary Fatigue perceived through the FSS (Fatigue Severity Scale) In order to evaluate the vulnerability and protective factors related to somatic disease fatigue will be evaluated. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity. 3 weeks
Secondary Cognitive disorders through the SDMT (Symbol Digit Modalities Test) In order to evaluate the vulnerability and protective factors related to somatic disease cognitive disorders will be evaluated The SDMT is a sign coding test that assesses attentional abilities (sustained attention and speed of processing information). Participants are required to use a coded key to match nine abstract symbols paired with numerical digits. The final score is the correct number of substitutions in 90 seconds, and scores range between 0 and 110. 3 weeks
Secondary Anxiety-depressive symptoms measured by the Hospital Anxiety and Depression Scale (HADS) The vulnerability and protective factors linked to psychological functioning- as Anxiety-depressive symptoms will be determined.
- Personality traits: Big Five Inventory-FR questionnaire (BFI-FR)
3 weeks
Secondary Personality traits measured by the Big Five Inventory-FR questionnaire (BFI-FR) The vulnerability and protective factors linked to psychological functioning as personality traits will be determined.
The Big Five personality traits is a suggested grouping for personality traits. The theory identifies five factors:
openness to experience (inventive/curious vs. consistent/cautious)
conscientiousness (efficient/organized vs. extravagant/careless)
extraversion (outgoing/energetic vs. solitary/reserved)
agreeableness (friendly/compassionate vs. challenging/callous)
neuroticism (sensitive/nervous vs. resilient/confident)
3 weeks
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis